PRIMARY RESEARCH | PUBMED LINKS
DRUG CATEGORY: PEPTIDES+ (ANTI-AGING)
DRUG NAME: FOXO4-DRI

• FDA Safety Data Sheet not available (experimental peptide).

• Li Y. FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Exp Gerontol. 2024 [PubMed Link]

• Kong YX. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Commun Biol. 2025 [PubMed Link]

• Zhang C. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020 [PubMed Link]

• Born E. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation. 2023 [PubMed Link]

• Huang Y. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Front Bioeng Biotechnol. 2021 [PubMed Link]

• Bourgeois B. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun. 2025 [PubMed Link]

• Meng J. Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis. JCI Insight. 2021 [PubMed Link]

• Valentijn FA. Cellular senescence in the aging and diseased kidney. J Cell Commun Signal. 2018 [PubMed Link]

• van Willigenburg H. Cellular senescence as a therapeutic target to improve renal transplantation outcome. Pharmacol Res. 2018 [PubMed Link]

• Krimpenfort P. Rejuvenation by Therapeutic Elimination of Senescent Cells. Cell. 2017 [PubMed Link]